Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Beauvericin: The Journey of a Pesticide into a Humanized Drug

Version 1 : Received: 20 July 2021 / Approved: 22 July 2021 / Online: 22 July 2021 (07:48:33 CEST)

How to cite: Al Khoury, C.A.; Nemer, N.; Tokajian, S.; Nemer, G. Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints 2021, 2021070506 (doi: 10.20944/preprints202107.0506.v1). Al Khoury, C.A.; Nemer, N.; Tokajian, S.; Nemer, G. Beauvericin: The Journey of a Pesticide into a Humanized Drug. Preprints 2021, 2021070506 (doi: 10.20944/preprints202107.0506.v1).

Abstract

Drug discovery has been initially attributed to coincidence or trial and error where the traditional approach was complex, lengthy, and expensive. Conventional drug discovery methods require the costly random screening of synthesized compounds or natural products. Another downside for this approach is the wide dependency on the experimental use of animals for in vi-vo testing. Currently, in silico modeling has become a vital tool for drug discovery and repurposing, and molecular docking is being used to find the best matching between a ligand and a molecule. Practical application of in silico docking will predict the biomolecular interactions between the drug and the target host. Beauvericin (BEA) is an emerging mycotoxin produced by the entomopathogenic fungus Beauveria bassiana. Originally investigated for its pesticide capability, BEA is now considered as a molecule of interest for its potentially diverse biotechnological applications in the pharmacological industry and the field of medicine. In this manuscript, we will provide an overview of the repurposing of BEA into a potentially superior therapeutic molecule in a broad range of diseases. Furthermore, considerable attention has been given to the fundamental role of in silico techniques to i) further investigate the spectrum of this secondary metabolite and ii) elucidate the pathways of BEA for its promising therapeutic action

Keywords

Drug repositioning; Molecular modelling; Beauvericin

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.